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Abstract 
Symptoms of hyperammonemia are age-dependant; some are reversible.  Multiple 
mechanisms are involved.  Hyperammonemia increases the uptake of tryptophan into the 
brain by activation of the L-system carrier; brain glutamine plays a still undefined role.  The 
uptake of tryptophan by the brain is enhanced if the levels of branched-chain amino acids 
competing with the other large neutral amino acids are low in plasma.  Hyperammonemia 
increases the utilization of branched-chain amino acids in muscle when ketoglutarate is low; 
this is further enhanced with glutamine depletion (using phenylbutyrate).  Anorexia, most 
likely a serotoninergic symptom, might further aggravate the deficiency of indispensable 
amino acids (branched-chain and arginine).  The role of increased glutamine production in 
astrocytes and the excitotoxic and metabotropic effects of increased extracellular glutamate 
have been extensively described.  They differ between models of acute and chronic 
hyperammonemia.  Using an in vitro model of cultured embryonic rat brain cell aggregates, 
we studied the role of creatine.  Cultures exposed to ammonia before maturation showed 
impaired cholinergic axonal growth accompanied by a decrease of creatine and 
phosphocreatine, a finding not seen in mature cultures.  By using different antibodies we have 
shown that the phosphorylated form of the intermediate neurofilament protein is affected.  
Adding creatine to the culture medium partially prevents impairment of axonal growth.  The 
presence of glia in the culture is a precondition for this protective effect.  Adequate arginine 
substitution is essential in the treatment of urea cycle defects as creatine is inefficiently 
transported into the brain.  
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Introduction 
Hyperammonemic disorders in pediatrics and especially urea cycle defects (UCD) present 
with both reversible and irreversible disabling symptoms, the mechanisms of which are not 
fully understood.  In patients and in experimental animal models the various mechanisms are 
often additive or interacting, leading to a vicious cycle that renders a therapeutic intervention 
difficult and challenging or makes the interpretation of experimental results tedious.  
Therapeutic schemes and recommendations are useful as a starting point, but a better 
understanding is needed for the interpretation of the dietary history, symptoms and 
biochemical control data and, consequently, for timely changes in the treatment of an 
individual patient to prevent further irreversible damage.  Our aim is to understand the main 
mechanisms of the irreversible, disabling effects of hyperammonemia on the patients during 
their development  and especially those affecting the central nervous system (CNS) that lead 
to the poor long term prognosis of surviving patients even treated by using the actual 
conservative therapy [1].  
  
Ammonia, large neutral amino acids and glutamine 
The pathophysiologic mechanisms of toxicity of ammonia and its metabolites on the brain 
have been reviewed recently [2] [3] [4].  The effects of an acute increase in plasma ammonia 
should be distinguished, both clinically and experimentally, from chronic moderate increases 
[5].  Changes of metabolites other than ammonia in blood also affect the brain.  As 
summarized by Gropman and Batshaw [6] the transport of tryptophan, the precursor of 
serotonin, from blood to brain, is increased in the hyperammonemic brain. This is caused by: 
a) a decrease in large neutral amino acids, mainly branched-chain amino acids (BCAA), that 
compete with tryptophan for the usually saturated transporter (mainly system L1) of large 
neutral amino acids (LNAA). Hyperammonemia decreases BCAA in plasma and muscle as 
 4
important nitrogen donors for glutamine synthetase. BCAA deficiency and to a lesser extent 
decreased levels of other proteogenic amino acids will hinder protein synthesis by increasing 
excessively insulin like growth factor (IGF) binding protein expression [7] [8] as compared to 
IGF and thus increase catabolism and ammonia load. The clinical observations by Maestri et 
al [9] indicate that the glutamine depletion effected by phenylbutyrate application adds to the 
decrease of BCAA.  This is supported by experimental data [10].  It is not clear whether the 
beta oxidation of phenylbutyrate (medium chain acyl dehydrogenase) is enhancing the leucine 
oxidation in tissue. 
 b) an increased activity/density of the luminal transporter(s) of the brain microvessels.  
The increase of tryptophan leads to an increased synthesis and release of serotonine and thus 
might induce anorexia[11,12]; this symptom often found in UCD patients renders  them prone 
to chronic catabolism and malnutrition and thus to increased ammonia load resulting in a 
vicious cycle. 
 
Is glutamine in plasma and/or in the brain increasing tryptophan uptake at the blood 
brain barrier? 
There is confusion in case reports as to the comparative roles of plasma and brain glutamine.  
Is plasma glutamine solely a marker of the ammonia metabolism in the periphery or is it 
directly involved in the pathogenesis of neurologic symptoms? 
Plasma glutamine can be viewed as the extracellular transport form of glutamate.  The 
increase of plasma glutamine in UCD indicates that its production in tissue might be increased 
and that the capacity of the urea cycle in the liver, located near the portal vessels as first line 
of defense, is insufficient, but that the hepatic perivenous glutamine synthesis as second line 
of ammonia detoxication in the liver is functioning.  This implies that splanchnic blood does 
not bypass the liver and that liver glutamate dehydrogenase is functioning normally.  
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Glutamine in brain is formed mainly within astrocytes from ammonia and intermediates of 
glucose and fatty acids metabolism (octanoate 20%; [13]).  Unidirectional influx from the 
blood in anesthetized rats is only 5 nmol/g per minute as compared to a rate of glutamine 
synthesis within the brain in normal rats of 40 nmol/g per minute that can increase up to 200 
nmol/g [14].  
Experimentally, an increased concentration of glutamine within brain microvessel cells 
enhances the transport of LNAA into the tissue.  This is true (in bovine microcapillaries) for 
L- and for D-glutamine [11] [15] [2].  The use of inhibitors of glutathione synthesis (acivicin, 
methionine sulfoximine, or specifically buthionine sulfoximine) indicates that 
gammaglutamyl transfer, located at the luminal side of brain capillaries, plays a role in the 
transport of tryptophan [16] [2].  Other glutamine transport systems (system N, A and B0,+ [16]) 
are active at the abluminal  side of the blood brain barrier. 
As D-glutamine is a poor substrate for system-L and as - to our knowledge - no racemase 
converting D- into L-glutamine has been shown in mammals, the increased transport of 
LNAA under hyperammonemic conditions does not simply occur by exchange with 
glutamine catalyzed by the system-L transporter(s) but by a mechanism that is not fully 
understood.  
Since there is a net arterio-venous difference in chronic experimental hyperammonemia 
indicating that transport of glutamine out of the brain prevails, it is likely that the 
concentration of ammonia in the brain is more relevant than that in plasma for the stimulation 
of tryptophan uptake into the brain.  This hypothesis is supported by the lack of correlation 
between the plasma concentrations of glutamine and tryptophan in urease-injected rats [17].  
Interestingly, Hammond et al. [18] reported increased concentrations of gamma-
glutamylglutamine in plasma and CSF taken from hyperammonemic patients.  It cannot be 
excluded that in CSF this compound originates from the gamma-glutamyl cycle expressed in 
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the choroid plexus.  It points to the fact that at high concentrations L-glutamine might be an 
acceptor substrate for gamma-glutamyl transferase, provided glutathione is not limiting.   
In models of brain edema, where lethal doses of ammonia are administered, glial fibrillary 
acidic protein (GFAP) is reduced [19] and glutamine is increased in brain [20]; this latter is 
preceded by an increase in cerebral blow flow [21].  Whether nitrous oxide (NO) production in 
brain capillary endothelia plays a role is not clear.  NO could also originate from brain cells, 
as the arginine recycling enzymes are induced in astrocytes by ammonium [22].  The 
constitutive NO synthetase of brain (nNOS) as well as the NO cycle enzyme 
argininosuccinate synthetase are not expressed in astrocytes of normal adult rats; the other 
players in the NO cycle argininosuccinate lyase, arginase2 and the cationic amino acid 
transporter CAT1 are found in neurons and glial cells, but expressed to a variable degree and 
dependent on location.  CAT2B and CAT3 are not expressed in astrocytes [22] [23].  If NO is 
formed in astrocytes at the blood brain barrier then the reaction is catalyzed by the inducible 
NOS (if present).  In contrast to most animal models plasma arginine is very low in patients 
with urea cycle defects (e.g. AL deficiency).  One might thus consider that at low brain 
arginine concentrations the stimulated nNOS in neurons might mainly produce O2- that 
combines with NO to form the highly toxic peroxynitrite. 
 
Glutamate 
Glutamate is not increased in astrocytes in hyperammonemia because glutamine formation 
from ammonium and glutamate prevails over glutamate synthesis.  Chronic moderate 
hyperammonemia impairs the activation of NMDA receptors and leads to a reduced reuptake 
of extracellular glutamate [25].  After prior exposure to ammonia, rat astrocytes in primary 
culture show a reduced production of free radicals after ammonium load as compared to that 
of an initial acute challenge [26]; cGMP formation in cerebellar neurons appears to be 
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stimulated and cGMP concentrations in brain microdialysate of chronic moderately 
hyperammonemic rats were found lower than in controls [25].  Neither neuronal NOS nor 
NMDA receptor activation was affected under these conditions.  
In contrast, acute hyperammonemia leads to excessive activation of NMDA receptors, 
increased intracellular Ca++, which bound to calmodulin, stimulates NOS; NO activates the 
guanylate cyclase (cerebellum) [27,28].  This difference between chronic and acute 
hyperammonemia might, at least in part, be explained by the neuromodulation of glutamate 
receptors by glutathione (for review see [29]).  In astrocyte cultures glutathione is increased by 
ammonium in a dose and time dependant way [30].  It is readily released from astrocytes [31].  
 
Creatine 
Animal experiments are plagued by the multiple variables that cannot be controlled (effects of 
the decrease of intake of chow and water in hyperammonemic rats, serotoninergic and more 
direct effects of ammonia mentioned above). To investigate the irreversible effects of 
ammonia increase we used aggregates of rat embryonic brain cells cultured in serum-free 
chemically defined medium [32] [33]. This method allows the culture of astrocytes, neurons, 
oligodendrocytes and microglia together and thus also to study intercellular interactions. 
Using this model, we showed that ammonia impairs axonal growth as well as medium weight 
neurofilament (NF-M ) expression and phosphorylation [34]. We have further demonstrated 
that ammonia impairs axons only during their maturation, but not when neurons have gone 
through synaptogenesis [34].   
 
We have shown that exposing brain cells to ammonia may alter the recycling of arginine, 
which plays key roles in CNS not only as substrate for protein synthesis or precursor of NO, 
but also as substrate for creatine synthesis; there is substantial evidence that creatine is 
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essential for axonal elongation [24] [34]. We have thus tested whether creatine metabolism is 
altered by ammonia, and shown that indeed NH4Cl exposure of brain cell aggregates leads to 
a decrease of intracellular creatine and phosphocreatine [34]. When the aggregate cultures are 
co-treated with creatine (1 mM) during NH4Cl (5 mM) exposure, creatine protects the axons 
from growth impairment to a certain extent, in a glial cell dependent manner [34]. 
 
For a better understanding of the protective effect of creatine, we have analyzed the gene 
expression of the creatine synthesis pathway and transporter in the different cell types of 
CNS. This was achieved by in situ hybridization [35] and immunohistochemistry with specific 
antibodies for L-arginine:glycine amidinotransferase (AGAT, supplied by O.Speer and 
T.Wallimann), as well as for S-adenosyl-L-methionine:N-guanidinoacetate methyltransferase 
(GAMT) and for the creatine transporter (CRT1), developed in our laboratory. The anti-CRT1 
antibody was directed against amino acids 15-29 of the sequence [36]. AGAT and GAMT are 
expressed in astrocytes, oligodendrocytes and neurons whereas CRT1 is present in neurons 
and oligodendrocytes but cannot be detected in astrocytes, including those contacting 
capillaries [35]. Thus CRT1 in the brain may function predominantly as an intercellular 
transporter and not for bulk transport from the blood: the brain may thus depend to a large 
extent on local de novo synthesis of creatine. This is in accordance with the clinical 
observation in congenital defects of creatine synthesis or transport or in ornithine 
aminotransferase deficiency where supplementation of creatine at high doses over a prolonged 
period is necessary to increase its brain concentration to some extent without reaching full 
restoration. 
When aggregates were exposed to ammonia a moderate induction of CRT1 was observed in 
astrocytes, including those resembling Alzheimer type II cells. The normally high expression 
of CRT1 in oligodendrocytes was decreased by ammonia exposure. 
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As we have shown that exposing brain cell aggregates to ammonia induces arginine recycling 
enzymes in astrocytes [24], and decrease intracellular levels of creatine and phosphocreatine 
[34] , we further investigated the changes in intracellular concentrations of arginine as one key 
substrate of creatine synthesis  as well as of other amino acids in brain cell aggregates 
exposed to ammonia and/or creatine (13 days of culture, exposure from days 5 to 13; Table 
1). The concentration of arginine (substrate for AGAT) is increased by 1 mM ammonia 
exposure and remains on the same plateau level at higher concentrations (2.5 and 5 mM), 
while ornithine (product of AGAT) increases after exposure to 5 mM ammonia. In contrast 
the concentration of most essential amino acids drops at that level of ammonia as compared to 
lower ammonia concentrations except for branched chain amino acids. Levels of glutamate 
and its precursors, proline and alanine, decrease. The concentrations of most of the amino 
acids are lower with creatine co-treatment (Table 1).  Interestingly, for arginine the ammonia 
and creatine effects are non-additive. It is not clear whether at high ammonia concentrations 
there is competition between arginine and creatine for their transporters. 
 
Brain cell cytoskeletal elements have recently been found to be altered under 
hyperammonemic conditions. The phosphorylation of microtubule associated protein 2 
(MAP-2) is altered in the brain of hyperammonemic rats without liver failure with 
consequences on binding capacity to tubulin and its polymerisation [37] [38] [39] [40]. 
Furthermore we showed that the phosphorylation of NF-M is decreased in aggregates exposed 
to ammonia [34]. These findings must be viewed in the context of a more general alteration of 
protein phosphorylation as summarized recently by Corbalan et al. [41].  
 
As mitogen activated protein kinases (MAPK) are the main cascades linking extracellular 
signals to neuronal differentiation and axonal elongation, we started to investigate the 
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regulation of MAPK pathways in brain cell aggregates exposed to ammonia. Preliminary 
western blot data have been obtained, showing that upon exposure to ammonia  the 
phosphorylation of  Erk1/Erk2 increases in homogenates of mixed cell cultures, but decreases 
in neuron-enriched aggregates. The level of phosphorylation of SAPK/JNK is decreased both 
in mixed cell and neuron enriched cultures [42]. Further work is needed at the histological 
level to assess whether these changes vary uniformly among the cell types involved, or if 
these ammonia effects vary between glial cells and neurons. 
 
As to the link to ammonia and creatine it is of interest that the neuronal calcium-dependant 
reactive oxygen species production depends on a functioning MAPK pathway; this effect can 
be blocked by nerve growth factor application [43]. However whether this applies to NO 
and/or peroxynitrite (mentioned above) is not known. The Erk1/Erk2 and SAPK/JNK signal 
transduction cascades also play a role in gene transcription following NMDA receptor 
stimulation [44] [45].  In vivo, 5-HT1A post-synaptic receptor activation reduces phospho-Erk2 
levels in the hippocampus, but not in the striatum or frontal brain. Interestingly, there is no 
effect on SAPK/JNK or p38 MAPK [46]. 
 
Conclusions 
In clinical practice the first step in the treatment of hyperammonemic crises is to stop the 
nitrogen load, be it nutritional in origin and/or due to catabolism.  When managing patients 
with diagnosed UCD a depletion of arginine and of indispensable amino acids should be 
prevented by replacing if needed a part of natural protein by a special mixture of essential 
amino acids with high branched chain and low aromatic acids.  This will not only improve the 
quality of the limited natural protein ingested but also correct any imbalance with its 
consequences to the brain. 
 11
Despite the protective action of creatine on axonal development, supplementing creatine as 
such does not seem to be promising, as the brain seems well protected against excessive 
creatine influx.  However its precursor, L-arginine, which is low in the plasma of untreated 
patients with UCD (except for arginase deficiency), must be supplemented in sufficient 
amounts.  It is readily transported into the brain and needed for creatine, protein and NO 
synthesis.  
 
Acknowledgement: Supported by Swiss National Science Foundation (grants n° 3100-63892 
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Table 1. Intracellular amino acid concentrations (µmol/g protein) of mixed cultured 
aggregates harvested at 13 days after being exposed from days 5 to 13 to ammonia and / 
or creatine as indicated on top. 
 
Legend to Table 1 
Factorial analysis (n=3 per condition) shows a highly significant ammonia effect (p< 0.001) 
for all amino acids except for arginine, glutamine, serine, aspartate with significance of 
0.001<p< 0.01 and not significant for histidine, valine, ornithine, GABA, cysteine and 
citrulline. The creatine effect was highly significant (p< 0.001) for all amino acids except 
arginine, GABA, glycine and serine reaching a level of 0.001<p<0.01; not significant: 
ornithine, cysteine and citrulline. Significant interactions, i.e. non-additive effects of ammonia 
and creatine, were found for leucine and asparagine (p< 0.05), cystathionine (p=0.026) and 
especially arginine (p=0.020). 
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Creatine (mM) 0 0 0 0 1 1 1 1 
NH4+ (mM) 0 1 2.5 5 0 1 2.5 5 
Phenylalanine 8.8±0.86 9.0±1.47 9.0±0.18 7.1±0.45 7.6±0.24 7.2±0.25 6.5±0.56 5.6±0.15 
Tyrosine 9.8±0.93 10.2±1.48 9.9±0.36 7.8±0.07 8.6±0.3 8.0±0.2 7.5±0.45 6.1±0.12 
Methionine 2.7±0.26 2.5±0.46 2.5±0.27 2.1±0.19 2.4±0.01 2.2±0.09 2.0±0.09 1.7±0.16 
Leucine 5.9±0.54 6.9±1.45 8.0±0.18 9.4±0.19 5.4±0.34 5.6±0.2 6.1±0.4 6.8±0.23 
Isoleucine 6.1±0.61 7.4±1.6 8.2±0.23 9.1±0.24 5.7±0.32 5.9±0.21 6.3±0.37 6.8±0.29 
Histidine 4.2±0.57 4.6±0.78 4.5±0.54 4.1±0.29 3.9±0.39 3.6±0.17 3.4±0.33 2.9±0.13 
Valine 9.3±0.75 10.3±1.7 10.9±0.35 10.8±0.31 8.4±0.31 8.2±0.03 8.3±0.59 8.0±0.2 
Threonine 46.5±6.15 46.6±5.73 42.5±2.15 32.4±0.82 37.4±1.75 35.2±1.09 29.4±2.39 23.9±0.84 
Arginine 5.4±0.33 6.9±0.78 7.3±0.47 7.3±0.27 6.0±0.68 6.4±0.16 6.7±0.46 6.0±0.32 
Lysine 27.9±3.34 30.7±2.85 29.1±1.83 21.5±0.48 25.6±1.4 24.7±0.54 22.8±1.9 17.5±0.24 
Ornithine 1.0±0.14 1.3±0.48 1.1±0.05 2.7±2.85 1.2±0.54 0.8±0.1 1.2±0.97 0.9±0.42 
Proline 22.2±6.14 19.8±1.36 18.5±1.41 10.5±0.78 14.7±0.24 13.0±0.9 11.4±1.28 8.8±0.6 
Glutamate 94.9±12.7 104.±11.5 93.1±9.19 38.1±0.37 83.9±4.81 85.7±0.76 69.3±6.56 32.9±1.03 
Glutamine 286±34.2 333±34 354±15.3 289±13.1 246±9.2 256±7.1 258±18 228±4.4 
γ-Aminobutyrate 40.8±10.76 42.1±5.05 43.8±2.4 36±3.93 36.1±1.77 34.4±2.93 33.3±4.09 28.2±3.07 
Glycine 39.5±4.73 38.2±4.37 30.1±1.91 22.8±4.29 37.1±2.4 33.3±1.45 24.1±2.44 16.3±0.83 
Taurine 226±37.1 256±23.2 262±11.7 184±8.9 194±4.6 193±4.3 187±14.6 145±12.2 
Cysteine 0.5±0.07 0.4±0.16 0.4±0.23 0.6±0.17 0.4±0.2 0.4±0.27 0.4±0.09 0.6±0.04 
Cystathionine 11.5±1.56 18.0±3.02 19.0±1.77 13.9±0.54 8.2±0.95 10.4±1.38 9.7±0.79 7.0±0.25 
Serine 9.2±1.91 11.4±2.44 11.7±0.93 20.9±8.17 9.7±1.71 10±0.85 10.8±2.35 11.0±1.69 
Alanine 17.7±2 17.1±2.12 13.9±1.98 6.7±3.14 12.7±0.6 11.5±0.72 8.0±1.55 4.2±0.2 
Aspartate 12.1±2.32 11.1±1.79 11.6±0.36 8.1±1.81 8.9±0.68 7.7±1.28 7.8±1.88 5.1±0.46 
Asparagine 3.4±0.46 3.2±0.18 2.7±0.21 1.5±0.28 2.3±0.14 2±0.03 1.4±0.15 1.0±0.26 
 
